Literature DB >> 21531884

Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy.

Robert A Kyle1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21531884      PMCID： PMC3084644          DOI： 10.4065/mcp.2011.0171

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  5 in total

1.  [Clinical experiences with sarcolysin in neoplastic diseases].

Authors:  N BLOKHIN; L LARIONOV; N PEREVODCHIKOVA; L CHEBOTAREVA; N MERKULOVA
Journal:  Ann N Y Acad Sci       Date:  1958-04-24       Impact factor: 5.691

2.  Multiple myeloma and acute myelomonocytic leukemia.

Authors:  R A Kyle; R V Pierre; E D Bayrd
Journal:  N Engl J Med       Date:  1970-11-19       Impact factor: 91.245

3.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

4.  Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

Authors:  Jean-Luc Harousseau; Michel Attal; Hervé Avet-Loiseau; Gerald Marit; Denis Caillot; Mohamad Mohty; Pascal Lenain; Cyrille Hulin; Thierry Facon; Philippe Casassus; Mauricette Michallet; Hervé Maisonneuve; Lotfi Benboubker; Frédéric Maloisel; Marie-Odile Petillon; Iain Webb; Claire Mathiot; Philippe Moreau
Journal:  J Clin Oncol       Date:  2010-09-07       Impact factor: 44.544

5.  Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.

Authors:  Xavier Leleu; Jérome Tamburini; Aldo Roccaro; Pierre Morel; Jacob Soumerai; Vincent Lévy; Mathieu Wemeau; Sandy Balkaran; Stephanie Poulain; Zachary R Hunter; Irene M Ghobrial; Steven P Treon; Veronique Leblond
Journal:  Clin Lymphoma Myeloma       Date:  2009-03
  5 in total
  3 in total

1.  Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.

Authors:  Brian L Burnette; Angela Dispenzieri; Shaji Kumar; Ann M Harris; Jeff A Sloan; Jon C Tilburt; Robert A Kyle; S Vincent Rajkumar
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

Review 2.  Smoldering multiple myeloma requiring treatment: time for a new definition?

Authors:  Angela Dispenzieri; A Keith Stewart; Asher Chanan-Khan; S Vincent Rajkumar; Robert A Kyle; Rafael Fonseca; Prashant Kapoor; P Leif Bergsagel; Arleigh McCurdy; Morie A Gertz; Martha Q Lacy; John A Lust; Stephen J Russell; Steven R Zeldenrust; Craig Reeder; Vivek Roy; Francis Buadi; David Dingli; Suzanne R Hayman; Nelson Leung; Yi Lin; Joseph Mikhael; Shaji K Kumar
Journal:  Blood       Date:  2013-10-21       Impact factor: 22.113

3.  Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.

Authors:  Utkarsh Painuly; Shaji Kumar
Journal:  Clin Med Insights Oncol       Date:  2013-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.